EUVIMEDEUVIMED entdecken
Crossref

Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria

Irene Zaghi, Monica Cricca, Jason A Roberts, Martina Brandolini, Claudia Colosimo iD, Sofia Montanari, Vittorio Sambri, Russell E Lewis

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Irene Zaghi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University Hospital of Galway, Newcastle Road, Galway H91YR71, Ireland. Hauptthemen laut MEDLINE: Drug Resistance, Multiple, Bacterial, Gram-Negative Bacteria, Drug Monitoring. Die Arbeit nennt 23 Literaturangaben. Gefördert von: European Society of Clinical Microbiology and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We investigated the use of time-to-positivity (Tpos), a readily available parameter measured from automated blood culture incubators, as a surrogate marker for serum antimicrobial activity during antibiotic treatment against ESBL- and carbapenemase-producing Klebsiella pneumoniae.

Methods

Banked human serum spiked with clinically representative concentrations of different antibiotics was injected into aerobic blood culture bottles containing 1 × 104 mL inoculum of K. pneumoniae isolates. The time required for the test inoculum to ‘grow through’ serum antibacterial activity (Tpos) was then measured over 24 h. Serum containing combinations of antibiotics were also tested using an 8 × 8 combination array to assess synergistic or antagonistic interactions.

Results

Tpos increased from <10 to >24 h with increasing serum antibiotic concentrations for all drug-isolate combinations tested with the EC50 Tpos of ∼17 h for all isolates. The EC50 for ceftazidime/avibactam (4:1) ranged from 5.73 mg/L (95% CI, 5.60–5.37) for a WT strain (MIC 0.125 mg/L) to 377 mg/L (95% CI, 356.26–398.41) for a resistant KPC-3-producing isolate (MIC 16 mg/L). Variation in observed Tpos was linked to isolate MIC (R2 = 0.94). Antibiotic combinations marginally increased serum Tpos (1–3 h) for most isolates with the exception of ceftazidime/avibactam + meropenem or aztreonam against KPC-3-producing isolates (increase of 10.36–11.61 h) or ceftazidime/avibactam + aztreonam against an NDM-2 isolate (increase of 10.33 h).

Conclusions

Tpos is a simple, reproducible marker of serum antibiotic activity against ESBL- and carbapenemase-producing K. pneumoniae. With further clinical validation, Tpos could be developed as a complementary surrogate marker for early detection of inadequate antimicrobial therapy in patients receiving antibiotic therapy for bloodstream infections caused by MDR Gram-negative bacteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, Multiple, BacterialGram-Negative BacteriaDrug MonitoringKlebsiella pneumoniaeBlood CultureAnti-Bacterial Agentsbeta-LactamasesBacterial ProteinsKlebsiella InfectionsMicrobial Sensitivity TestsHumansTime Factors

Substanzen

Anti-Bacterial Agentscarbapenemasebeta-LactamasesBacterial Proteins

Autor:innen und Institutionen

  • Department of Infectious Diseases, University Hospital of Galway, Newcastle Road, Galway H91YR71, Ireland.
  • Unit of Microbiology, The Greater Romagna Area Hub Laboratory, Piazza della Liberazione 60, Cesena 47522, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, via Massarenti 9, Bologna 40138, Italy.
  • University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Building 71/918 RBWH Herston, Brisbane, Australia.
  • Herston Infectious Diseases Institute (HeiDI), Metro North Health, UQ Centre for Clinical Research Royal Brisbane and Women's Hospital, Herston, Brisbane, QLD 4029, Australia.
  • Department of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Butterfield St., Herston, Brisbane, QLD 4029, Australia.

ORCID-Profile: Claudia Colosimo

Förderung

  • European Society of Clinical Microbiology and Infectious Diseases

Zitieren

APA

Zaghi, I., Cricca, M., Roberts, J. A., Brandolini, M., Colosimo, C., Montanari, S., Sambri, V., & Lewis, R. E. (2025). Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf276

Vancouver

Zaghi I, Cricca M, Roberts JA, Brandolini M, Colosimo C, Montanari S, et al. Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf276

BibTeX
@article{Zaghi2025,
  author = {Zaghi, Irene and Cricca, Monica and Roberts, Jason A and Brandolini, Martina and Colosimo, Claudia and Montanari, Sofia and Sambri, Vittorio and Lewis, Russell E},
  title = {Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf276}
}
Kostenlos starten →